التداخل بين بوتورفانول ونالتريكسون

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] .

Patients with current physiologic opioid dependence [see Warnings and Precautions ( 5.3 ) ] .

Patients in acute opioid withdrawal [see Warnings and Precautions ( 5.3 ) ] .

Any individual who has failed the naloxone challenge test or has a positive urine screen for opioids [see Warnings and Precautions ( 5.3 ) ] .

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics (4) .

Management of respiratory depression may include close observation, supportive measures, and use of opioid overdose reversal agents (e.g., naloxone, nalmefene), depending on the patient's clinical status [see OVERDOSAGE ].

If concomitant use is warranted, consider ‎prescribing naloxone for the emergency treatment of opioid overdose.

In patients who are not opioid dependent, naloxone has also been reported to be effective.